BioSight
Companies
Liquidia Corp logo

LQDA

NASDAQMORRISVILLE, NC
Liquidia Corp

Liquidia Corp is a commercial-stage biopharmaceutical company with an approved product, YUTREPIA (treprostinil), used in pulmonary arterial hypertension, and a clinical-stage pipeline including L606, utilizing its PRINT technology platform for drug delivery. The company also commercializes a fully substitutable generic treprostinil injection in collaboration with Sandoz and is pursuing label expansion opportunities for YUTREPIA.

Price history not yet available for LQDA.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar